Downloaded from http://gut.bmj.com/ on February 13, 2015 - Published by group.bmj.com
Gut Online First, published on January 7, 2015 as 10.1136/gutjnl-2014-308337 Inflammatory bowel disease
ORIGINAL ARTICLE
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study Walter Reinisch,1,2 Julián Panés,3 Sunil Khurana,4 Gabor Toth,5 Fei Hua,6 Gail M Comer,6 Michelle Hinz,6 Karen Page,6 Margot O’Toole,6 Tara McDonnell Moorehead,7 Hua Zhu,8 YanHui Sun,8 Fabio Cataldi6 ▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2014-308337). For numbered affiliations see end of article. Correspondence to Professor Julián Panés, Department of Gastroenterology, Hospital Clínic de Barcelona, Villarroel 170, Barcelona 08036, Spain; [email protected] Received 29 August 2014 Revised 3 December 2014 Accepted 4 December 2014
ABSTRACT Objective Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC. Anrukinzumab, a humanised antibody that inhibits human IL-13, was evaluated for the treatment of UC. Design In a multicentre, randomised, double-blind, placebo-controlled study, patients with active UC (Mayo score ≥4 and
Gut Online First, published on January 7, 2015 as 10.1136/gutjnl-2014-308337 Inflammatory bowel disease
ORIGINAL ARTICLE
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study Walter Reinisch,1,2 Julián Panés,3 Sunil Khurana,4 Gabor Toth,5 Fei Hua,6 Gail M Comer,6 Michelle Hinz,6 Karen Page,6 Margot O’Toole,6 Tara McDonnell Moorehead,7 Hua Zhu,8 YanHui Sun,8 Fabio Cataldi6 ▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ gutjnl-2014-308337). For numbered affiliations see end of article. Correspondence to Professor Julián Panés, Department of Gastroenterology, Hospital Clínic de Barcelona, Villarroel 170, Barcelona 08036, Spain; [email protected] Received 29 August 2014 Revised 3 December 2014 Accepted 4 December 2014
ABSTRACT Objective Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC. Anrukinzumab, a humanised antibody that inhibits human IL-13, was evaluated for the treatment of UC. Design In a multicentre, randomised, double-blind, placebo-controlled study, patients with active UC (Mayo score ≥4 and
